EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR mutation + KRAS mutation	Non Small Cell Lung Cancer	EGFR mutation + KRAS mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + KRAS mutation	Lung Adenocarcinoma	EGFR mutation + KRAS mutation	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + KRAS mutation	Colorectal Cancer	EGFR mutation + KRAS mutation	Colorectal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D

EGFR mutation + KRAS mutation

Associations